Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 6/20 | 0.35 |
| ▸ | SCN5A known ✓ | Q14524 | 6/20 | 0.35 |
| ▸ | SCN8A known ✓ | Q9UQD0 | 6/20 | 0.35 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 0.33 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 5/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | SCN1B | Q07699 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175752 | 0.98 | ALDH1A1 (0.42) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL3516836 | 0.98 | ALDH1A1 (0.42) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL175753 | 0.98 | ALDH1A1 (0.42) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| Hydrochloric Acid SCHEMBL6498236 | 0.83 | SCN9A (0.34) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| SCHEMBL7288378 | 0.83 | PIK3CA (0.36) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| SCHEMBL6616473 | 0.81 | SCN9A (0.35) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| SCHEMBL6211278 | 0.81 | SCN9A (0.35) | ALDH1A1KDM4ESCN1ASCN5ASCN8A | |
| Gabapentin SCHEMBL3169310 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EMCL1BCL2HPGD | |
| SCHEMBL7299956 | 0.74 | KDM4E (0.35) | ALDH1A1KDM4EHPGDSCN1ASCN5A | |
| SCHEMBL9217841 | 0.72 | FPR2 (0.32) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5523289-A | RENIN INHIBITOR | ABBOTT LABORATORIES (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0456185-B1 | Renin inhibitors | ABBOTT LAB (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5344990-A | Process for the preparation of a renin inhibiting compound | ABBOTT LABORATORIES (US) | 1994-09-06 | — | — | US | disclosed |
| US-5332742-A | Ocular hypotensive | ABBOTT LABORATORIES (US) | 1994-07-26 | — | — | US | disclosed |
| US-5310740-A | Congestive heart failure, hypotensive agents, antiglaucoma agents; side effect reduction | ABBOTT LABORATORIES (US) | 1994-05-10 | — | — | US | disclosed |
| US-5284849-A | Treating hypertension and congestive heart failure | ABBOTT LABORATORIES (US) | 1994-02-08 | — | — | US | disclosed |
| US-5275950-A | Process for the preparation of a renin inhibiting compound | ABBOTT LABORATORIES (US) | 1994-01-04 | — | — | US | disclosed |
| US-5276031-A | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1994-01-04 | — | — | US | disclosed |
| US-5258362-A | Enzyme inhibitors, amides with oxetane ring | ABBOTT LABORATORIES (US) | 1993-11-02 | — | — | US | disclosed |
| WO-1993007886-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CERTAIN PEPTIDOMIMETIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1993-04-29 | — | — | WO | disclosed |
| WO-1993002667-A1 | PHARMACEUTICAL COMPOSITION | ABBOTT LABORATORIES (US) | 1993-02-18 | — | — | WO | disclosed |
| US-5182266-A | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1993-01-26 | — | — | US | disclosed |
| US-5178877-A | Cardiovascular disorders | ABBOTT LABORATORIES (US) | 1993-01-12 | — | — | US | disclosed |
| WO-1992022313-A1 | RENIN INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 1992-12-23 | — | — | WO | disclosed |
| US-5122514-A | Administering renin inhibitor | ABBOTT LABORATORIES (US) | 1992-06-16 | — | — | US | disclosed |
| EP-0456185-A2 | Renin inhibitors | ABBOTT LABORATORIES (US) | 1991-11-13 | — | — | EP | disclosed |
| US-5063208-A | Cardiovascular disorders, vision defects | ABBOTT LABORATORIES (US) | 1991-11-05 | — | — | US | disclosed |
| EP-0440102-A1 | Method for treating renal disease | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| EP-0410260-A2 | Peptidyl aminodiol renin inhibitors | ABBOTT LABORATORIES (US) | 1991-01-30 | — | — | EP | disclosed |